Quarterly infographic: MRSA, MSSA and Gram-negative bacteraemia and CDI, data up to January to March 2026
Updated 9 July 2026
Applies to England
Gram-negative bacteraemias (Klebsiella spp.,P. aeruginosa and E. coli)
Pseudomonas aeruginosa (P. aeruginosa) bacteraemia
January to March 2025: 6.7 out of every 100,000 persons developed a P. aeruginosa bacteraemia.
January to March 2026: 7.3 out of every 100,000 persons developed a P. aeruginosa bacteraemia.
Klebsiella spp. bacteraemia
January to March 2025: 21.9 out of every 100,000 persons developed a Klebsiella spp. bacteraemia.
January to March 2026: 22.8 out of every 100,000 persons developed a Klebsiella spp. bacteraemia.
Escherichia coli (E. coli) bacteraemia
January to March 2025: 71.6 out of every 100,000 persons developed an E. coli bacteraemia.
January to March 2026: 71.9 out of every 100,000 persons developed an E. coli bacteraemia.
Staphylococcus aureus (S. aureus) MRSA and MSSA bacteraemia and Clostridioides difficile (C. difficile) infections
Meticillin-resistant Staphylococcus aureus (MRSA) bacteraemia
January to March 2025: 1.8 out of every 100,000 persons developed an MRSA bacteraemia.
January to March 2026: 2.1 out of every 100,000 persons developed an MRSA bacteraemia.
Meticillin-susceptible Staphylococcus aureus (MSSA) bacteraemia
January to March 2025: 23.9 out of every 100,000 persons developed an MSSA bacteraemia.
January to March 2026: 23.9 out of every 100,000 persons developed an MSSA bacteraemia.
Clostridioides difficile (C. difficile) infection
January to March 2025: 29.2 out of every 100,000 persons developed a C. difficile infection.
January to March 2026: 28.1 out of every 100,000 persons developed a C. difficile infection.